MRTXMirati Therapeutics, Inc.

Nasdaq mirati.com


$ 58.72 $ -0.10 (-0.17 %)    

Monday, 22-Jan-2024 15:59:59 EST
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 58.7
$ 58.90
$ 0.00 x 0
$ 0.00 x 0
$ 58.54 - $ 58.95
$ 27.30 - $ 64.41
20,994,430
na
3.82B
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2023 09-30-2023 10-Q
2 08-08-2023 06-30-2023 10-Q
3 05-09-2023 03-31-2023 10-Q
4 02-28-2023 12-31-2022 10-K
5 11-08-2022 09-30-2022 10-Q
6 08-03-2022 06-30-2022 10-Q
7 05-04-2022 03-31-2022 10-Q
8 02-28-2022 12-31-2021 10-K
9 11-08-2021 09-30-2021 10-Q
10 08-05-2021 06-30-2021 10-Q
11 05-06-2021 03-31-2021 10-Q
12 02-25-2021 12-31-2020 10-K
13 11-04-2020 09-30-2020 10-Q
14 08-06-2020 06-30-2020 10-Q
15 05-07-2020 03-31-2020 10-Q
16 02-26-2020 12-31-2019 10-K
17 11-04-2019 09-30-2019 10-Q
18 08-05-2019 06-30-2019 10-Q
19 04-29-2019 03-31-2019 10-Q
20 02-28-2019 12-31-2018 10-K
21 11-06-2018 09-30-2018 10-Q
22 08-01-2018 06-30-2018 10-Q
23 05-07-2018 03-31-2018 10-Q
24 03-08-2018 12-31-2017 10-K
25 11-01-2017 09-30-2017 10-Q
26 08-03-2017 06-30-2017 10-Q
27 05-04-2017 03-31-2017 10-Q
28 03-09-2017 12-31-2016 10-K
29 11-03-2016 09-30-2016 10-Q
30 08-04-2016 06-30-2016 10-Q
31 05-05-2016 03-31-2016 10-Q
32 03-09-2016 12-31-2015 10-K
33 11-06-2015 09-30-2015 10-Q
34 08-06-2015 06-30-2015 10-Q
35 05-06-2015 03-31-2015 10-Q
36 03-11-2015 12-31-2014 10-K
37 11-10-2014 09-30-2014 10-Q
38 08-08-2014 06-30-2014 10-Q
39 05-15-2014 03-31-2014 10-Q
40 03-17-2014 12-31-2013 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 upward-trajectory-for-biotechpharma-ma-sector-trends-towards-pre-pandemic-levels-forecasts-positive-for-2024

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...

 enersys-to-rally-around-20-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 citigroup-downgrades-mirati-therapeutics-to-neutral-raises-price-target-to-59

Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and raises the price ta...

 leerink-partners-downgrades-mirati-therapeutics-to-market-perform-lowers-price-target-to-58

Leerink Partners analyst Andrew Berens downgrades Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Market Perform and lo...

 appian-to-rally-around-47-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 stifel-downgrades-mirati-therapeutics-to-hold-lowers-price-target-to-59

Stifel analyst Benjamin Burnett downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Hold and lowers the price target fr...

 opdivos-subcutaneous-formulation-shows-promise-in-advanced-kidney-cancer-bristol-myers-squibbs-latest-findings

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneou...

 mirati-presents-late-breaking-results-evaluating-combination-of-adagrasib-and-pembrolizumab-in-first-line-non-small-cell-lung-cancer

These data demonstrate a manageable safety profile and early signs of durability of adagrasib in combination with a checkpoint ...

 piper-sandler-downgrades-mirati-therapeutics-to-neutral-announces-58-price-target

Piper Sandler analyst Joseph Catanzaro downgrades Mirati Therapeutics (NASDAQ:MRTX) from Overweight to Neutral and announces...

 why-parazero-technologies-shares-are-trading-higher-by-over-100-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian re...

 stocks-halt-gains-oil-treasuries-rally-as-investors-react-to-israel-hamas-conflict-whats-driving-markets-monday

Markets kicked off the week with heightened volatility due to the ongoing conflict between Israel and the Palestinian militant ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION